ArticleFrontiers in cardiovascular medicine2026
THR-123, a novel BMP-7 mimetic that activates Akt phosphorylation and inhibits cardiomyocyte apoptosis and inflammation, protects the heart from myocardial injury in a Rat model.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myocardial infarction (AMI) continues to be the most common cause of heart failure despite the advancements in the treatment of Myocardial Infarction (MI) over the past 20 years. We have developed "BMP mimetics" that selectively activate the BMP signaling pathway, and do not induce bone formation. A BMP-7 mimetic, THR-123, is anti-inflammatory, anti-apoptotic, anti-fibrotic and promotes tissue regeneration. In an animal model of ischemia-reperfusion using LAD coronary occlusion-induced myocardial injury, THR-123 markedly decreased myocardial infarct size (84%) and pericardial inflammation. The mechanism of action of THR-123 was examined in three different cellular (cardiomyocytes) models. Mechanistically, THR-123 activates Akt phosphorylation and inhibits inflammation and apoptosis in cardiomyocytes. These results show that the BMP-7 mimetic (THR-123) protects cardiomyocytes, and limits infarct size after myocardial ischemia and reperfusion injury. THR-123 may provide a novel pharmacological intervention in myocardial injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.